Tenofovir disoproxil fumarate/Emtricitabine

DRUG4 trials

Sponsors

University of Colorado, Denver, Johns Hopkins University, Indiana University, University of Nebraska

Conditions

HIV InfectionsHIV PreventionPre-Exposure Prophylaxis

Early Phase 1

Assessment of a New Boosting Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers

CompletedNCT03202511

Indiana UniversityPre-Exposure Prophylaxis

Start: 2017-06-23End: 2018-07-02Updated: 2021-05-07

Phase 1

Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women

CompletedNCT03060785

Johns Hopkins UniversityHIV Prevention

Start: 2016-03-08End: 2018-05-31Updated: 2018-07-18

A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women

CompletedNCT03270969

University of NebraskaHIV Prevention

Start: 2018-01-05End: 2018-09-10Updated: 2023-09-15

Unknown Phase

Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection

CompletedNCT00414518

University of Colorado, DenverHIV Infections

Start: 2007-01-31End: 2010-02-28Updated: 2013-02-20

Related Papers

Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy

Journal of Antimicrobial Chemotherapy2020-01-1325 citations